Sector News

Allergan buys Kythera and its double-chin drug for $2.1bn

June 17, 2015
Life sciences
Dublin, Ireland-based Allergan is snapping up US group Kythera Biopharmaceuticals for a cool $2.1 billion, strengthening the firm’s foothold on the facial aesthetics scene.
 
The move gives Allergan access to Kythera’s lead product Kybella (deoxycholic acid) injection, the first and only approved non-surgical treatment for double chin (or severe submental fullness), which gained US clearance in April.
 
The acquisition will also bring setipiprant (KYTH-105) – a novel compound for the prevention of male pattern baldness – into Allergan’s pipeline, as well as a batch of other early-stage development candidates.
 
Under the deal, which remains subject to customary closing conditions, the Irish drugmaker will pay $75 per Kythera share in a mix of cash and stock, valuing the transaction at around $2.1 billion.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”